We have already shown that the mere assessment of the extent of inflammation in the TME of OSCC was not by itself powerful enough to indicate clinical outcomes, but more specifically the extent of pro-tumorigenic immune cells [e.g., regulatory T cells (Tregs, FOXP3+) and tumor-associated macrophages (TAM2, CD163+)] were key features in determining patients' prognosis [22]. This evidence concerns the gene CD163 and neoplasm.